finance.yahoo.com ·
phibro animal health q3 earnings 182020928
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedPhibro Animal Health reported solid Q3 results with growth in Animal Health and Mineral Nutrition segments. Regulatory changes in Brazil may impact antimicrobial sales, but mitigation via new approvals is planned. The impact is company-specific, with potential regulatory risk in Brazil affecting future revenue from certain products.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Phibro Animal Health Q3 FY2026 net sales $383.5M, +10% YoY
- Adjusted EBITDA $60M, +11% YoY
- Animal Health segment sales $291.2M, +13% YoY
- Mineral Nutrition sales +10%, Performance Products -17%
- FY2026 guidance raised: net sales $1.46-1.50B, EBITDA $247-255M
Brazil regulatory risk on antimicrobials may offset growth, limiting mid-term upside for Phibro and peers.
Sign in to see all sector verdicts, full thesis and counter-argument debate.